1. Recent Advances in the Management of Typical and Atypical Lung Carcinoids
- Author
-
Michele Prisciandaro, Carlo Spreafico, Massimo Milione, Claudia Proto, Francesca Corti, Alessandra Raimondi, Jorgelina Coppa, Giovanni Leuzzi, Maria Di Bartolomeo, Sara Pusceddu, Martina Torchio, Tommaso Cascella, Natalie Prinzi, Filippo de Braud, Roberta Elisa Rossi, Giuseppe Lo Russo, Teresa Beninato, and Elena Colombo
- Subjects
0301 basic medicine ,Pulmonary and Respiratory Medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Poor prognosis ,Lung Neoplasms ,Carcinoid Tumor ,Neuroendocrine tumors ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Epidemiology ,Humans ,Medicine ,Lung cancer ,Patient Care Team ,Lung ,business.industry ,Incidence ,Poorly differentiated ,medicine.disease ,Neuroendocrine Tumors ,Locoregional disease ,030104 developmental biology ,medicine.anatomical_structure ,Current management ,030220 oncology & carcinogenesis ,business - Abstract
Neuroendocrine neoplasms of the lung represent about 20% to 30% of all neuroendocrine tumors. On the basis of clinical and pathologic characteristics, 2 different categories of tumors may be defined: poorly differentiated neuroendocrine neoplasms, characterized by a high rate of recurrences and poor prognosis, and well-differentiated neuroendocrine neoplasms (typical carcinoids and atypical carcinoids), which generally display an indolent course. Lung carcinoids represent only 1% to 5% of all lung malignancies, but their incidence has significantly increased over the past 30 years. Surgery is the reference standard of treatment for lung carcinoids with locoregional disease. For advanced or unresectable lung carcinoids, several therapeutic options are available, but the choice should be shared within a multidisciplinary team to ensure optimal therapeutic outcomes. We describe the current management of these rare neoplasms.
- Published
- 2021
- Full Text
- View/download PDF